A colleague of Paul Sax, M.D., once posed the question, "Why do ID specialists even exist?" Saying, "There is nothing we do that other doctors couldn't also do, provided they had the motivation."
Paul Sax, M.D., discusses the clinical importance of new drugs in development highlighted at CROI 2017 -- and about what else is on the near horizon when it comes to antiretroviral therapies for HIV.
David Fawcett, Ph.D., L.C.S.W. admits he was a bit shocked by seeing rainbow-colored syringe packs, but asks, "Can we really afford not to utilize every tool we have to prevent HIV and HCV?"
This infographic from AVAC looks ahead at the status of large-scale prevention trials through 2020.
A recent study, published this month in JAIDS, gives insight into the challenges of PrEP uptake by young gay men of color.
"My work in South Africa is showing that managed HIV encounters a variety of social and environmental challenges that confront the possibility for healthy lives," Brian King writes.
Keiko Lane, M.F.T., finds herself connecting over the pain of losing so many to AIDS, even as she shares today's HIV prevention options with a gay, immigrant hotel worker in a serodiscordant relationship.
Linda-Gail Bekker provides an overview of the new frontiers in HIV prevention.